Attention! Biointeractive will not be available during maintenance on Tuesday, February 27, from 5-8PM ET. We apologize for any inconvenience.Gleevec-Resistant BCR-ABL
This model shows a mutated form of the cancer-causing protein BCR-ABL that is resistant to the drug Gleevec.
Gleevec is a drug for treating chronic myeloid leukemia (CML), a cancer of white blood cells. In CML, white blood cells divide uncontrollably due to an overactive tyrosine kinase protein called BCR-ABL. Although Gleevec usually blocks the activity of BCR-ABL, it is unable to bind to the mutant form of BCR-ABL shown in this model. The model shows the ABL kinase domain of the mutant protein, which includes a binding site for ATP.
The 3D model can be viewed and rotated in the online 3D Viewer. The accompanying downloads provide other ways to display and interact with the model. The “3D Preview” contains an image of the model that can be viewed and rotated within Adobe Acrobat. The “3D Movie Loop” is a short looping animation that shows the model being rotated. The “3D Printing Data” STL file allows the model to be printed on a 3D printer.
Note that the STL file can be viewed with the free MakerWare software from MakerBot, but MakerWare will print only to a MakerBot printer. Please use the software provided with your 3D printer to print the STL file.
cancer, dasatinib, Gleevec, health care, imatinib, medicine, mutation, protein, resistance, tyrosine kinase
The resource is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. No rights are granted to use HHMI’s or BioInteractive’s names or logos independent from this Resource or in any derivative works.